The steroidogenic inhibitor finasteride reverses pramipexole-induced alterations in probability discounting.

5-alpha Reductase Inhibitors / pharmacology Animals Behavior, Animal / drug effects Choice Behavior / drug effects Disease Models, Animal Dopamine Agonists / pharmacology Finasteride / pharmacology Impulsive Behavior / drug effects Nucleus Accumbens / drug effects Pramipexole / pharmacology Probability Learning Rats Receptors, Dopamine D3 / agonists
D(3) dopamine receptors Finasteride Nucleus accumbens Pramipexole Probability discounting

Journal

Brain research bulletin
ISSN: 1873-2747
Titre abrégé: Brain Res Bull
Pays: United States
ID NLM: 7605818

Informations de publication

Date de publication:
04 2022
Historique:
received: 01 11 2021
revised: 21 01 2022
accepted: 29 01 2022
pubmed: 6 2 2022
medline: 1 4 2022
entrez: 5 2 2022
Statut: ppublish

Résumé

Pramipexole is a potent agonist of D

Identifiants

DOI: 10.1016/j.brainresbull.2022.01.020 PMID: 35122898 PMC: PMC9012661
pubmed: 35122898
pii: S0361-9230(22)00032-6
doi: 10.1016/j.brainresbull.2022.01.020
pmc: PMC9012661
mid: NIHMS1778488
pii:
doi:

Substances chimiques

5-alpha Reductase Inhibitors 0
Dopamine Agonists 0
Drd3 protein, rat 0
Receptors, Dopamine D3 0
Finasteride 57GNO57U7G
Pramipexole 83619PEU5T

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

157-166

Subventions

Organisme : NIDA NIH HHS
ID : R21 DA049530
Pays : United States

Informations de copyright

Copyright © 2022 Elsevier Inc. All rights reserved.

Références

Neuropsychopharmacology. 2012 May;37(6):1397-408
pubmed: 22257895
Biomolecules. 2019 Nov 19;9(11):
pubmed: 31752360
Schizophr Res. 2015 Nov;168(3):640-8
pubmed: 25999042
Sci Rep. 2017 Jun 13;7(1):3348
pubmed: 28611376
Transl Psychiatry. 2019 Dec 10;9(1):337
pubmed: 31822658
Exp Clin Psychopharmacol. 2009 Oct;17(5):283-90
pubmed: 19803627
Psychoneuroendocrinology. 2016 Jan;63:59-67
pubmed: 26415119
Drugs Aging. 2013 Aug;30(8):587-92
pubmed: 23686524
J Clin Psychiatry. 1996 Aug;57(8):360-3
pubmed: 8752019
Am J Mens Health. 2015 May;9(3):222-8
pubmed: 24928450
Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3579-84
pubmed: 10737804
Curr Pharm Des. 2011;17(2):151-67
pubmed: 21361868
J Clin Psychiatry. 2012 Sep;73(9):1220-3
pubmed: 22939118
BMC Clin Pharmacol. 2006 Oct 07;6:7
pubmed: 17026771
Psychoneuroendocrinology. 2012 Oct;37(10):1630-45
pubmed: 22029952
Front Behav Neurosci. 2021 Apr 28;15:637074
pubmed: 33994967
BMJ. 2019 Aug 9;366:l5047
pubmed: 31399423
Basal Ganglia. 2015 Aug 1;5(2-3):51-55
pubmed: 26251824
Neurobiol Dis. 2010 Jul;39(1):98-104
pubmed: 20338240
Exp Clin Psychopharmacol. 2010 Jun;18(3):267-76
pubmed: 20545391
Pharmacotherapy. 2015 Jul;35(7):687-95
pubmed: 26133534
Int J Dermatol. 2019 Jul;58(7):759-776
pubmed: 30604525
Drug Saf. 2018 Jan;41(1):19-75
pubmed: 28861870
Psychoneuroendocrinology. 2013 Apr;38(4):542-51
pubmed: 22877998
Brain Pathol. 2015 Jul;25(4):377-90
pubmed: 25726735
Synapse. 2015 Apr;69(4):183-9
pubmed: 25645960
Eur J Pharmacol. 1995 Jun 23;290(1):29-36
pubmed: 7664822
Arch Gen Psychiatry. 2012 Feb;69(2):177-86
pubmed: 22310505
Hum Brain Mapp. 2011 May;32(5):800-11
pubmed: 21484950
Neuropharmacology. 2019 Mar 15;147:55-65
pubmed: 29907425
Am J Psychiatry. 1992 Apr;149(4):443-54
pubmed: 1372794
Exp Neurol. 2017 May;291:1-7
pubmed: 28131725
Neuropharmacology. 2019 Nov 15;159:107513
pubmed: 30716416
Arch Neurol. 2006 Jul;63(7):969-73
pubmed: 16831966
Arch Neurol. 2005 Sep;62(9):1377-81
pubmed: 16009751
Neurobiol Stress. 2019 Dec 26;12:100209
pubmed: 32435662
PLoS One. 2014 Mar 11;9(3):e91151
pubmed: 24618531
Drug Alcohol Depend. 2001 Jun 1;63(1):29-38
pubmed: 11297829
Subst Use Misuse. 1998 Nov;33(13):2535-60
pubmed: 9818989
J Affect Disord. 2021 Feb 1;280(Pt B):77-89
pubmed: 33242731
Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S80-4
pubmed: 22166463
Dermatol Ther. 2018 Mar;31(2):e12588
pubmed: 29464847
Proc Natl Acad Sci U S A. 1994 Nov 8;91(23):11271-5
pubmed: 7972046
J Pharmacokinet Biopharm. 1987 Dec;15(6):657-80
pubmed: 3450848
Behav Brain Res. 2013 Sep 1;252:24-31
pubmed: 23727149
J Clin Psychopharmacol. 2012 Jun;32(3):424-5
pubmed: 22534502
Rev Endocr Metab Disord. 2015 Sep;16(3):177-98
pubmed: 26296373
Neurology. 1999 Mar 23;52(5):938-43
pubmed: 10102409
Mol Autism. 2020 Jul 27;11(1):62
pubmed: 32718349
Neurology. 2003 Aug 12;61(3):422-3
pubmed: 12913220
Neuropsychopharmacology. 2017 Oct;42(11):2196-2205
pubmed: 28102229
JAMA Dermatol. 2021 Jan 1;157(1):35-42
pubmed: 33175100
Neuropharmacology. 2017 Mar 1;114:77-87
pubmed: 27889491
Neurology. 1997 Jul;49(1):162-8
pubmed: 9222185
Neuropsychopharmacology. 2009 Dec;34(13):2746-57
pubmed: 19710633
Eur Neuropsychopharmacol. 2020 Mar;32:104-119
pubmed: 31983530
J Clin Psychopharmacol. 2017 Feb;37(1):102-104
pubmed: 27930495
J Clin Endocrinol Metab. 1999 Apr;84(4):1304-10
pubmed: 10199771
World Psychiatry. 2016 Oct;15(3):297-298
pubmed: 27717269
PLoS One. 2020 Jan 7;15(1):e0227128
pubmed: 31910240
Alcohol Clin Exp Res. 2008 Aug;32(8):1408-16
pubmed: 18565155
Gynecol Endocrinol. 2003 Oct;17(5):419-22
pubmed: 14710591
Int J Addict. 1995 Feb;30(3):275-89
pubmed: 7790128
Drug Des Devel Ther. 2020 Mar 02;14:951-959
pubmed: 32184564
Transl Psychiatry. 2021 Feb 15;11(1):125
pubmed: 33589585
Mov Disord. 2017 Nov;32(11):1557-1565
pubmed: 28960475
Mov Disord. 2010 Aug 15;25(11):1660-9
pubmed: 20589879
Neuropsychopharmacology. 2008 Dec;33(13):3146-56
pubmed: 18354385
Addiction. 2018 Dec;113(12):2173-2181
pubmed: 30047179
Neurobiol Dis. 2019 Jan;121:120-130
pubmed: 30261284
J Clin Invest. 2021 May 17;131(10):
pubmed: 33848264
Arch Neurol. 2010 May;67(5):589-95
pubmed: 20457959
JAMA Intern Med. 2014 Dec;174(12):1930-3
pubmed: 25329919
J Biol Chem. 2003 Aug 8;278(32):29979-86
pubmed: 12775713

Auteurs

Gabriele Floris (G)

Dept. of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City, UT, USA.

Simona Scheggi (S)

Dept. of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City, UT, USA; Dept. of Molecular and Developmental Medicine, School of Medicine, University of Siena, Italy.

Romina Pes (R)

Dept. of Pharmacology and Toxicology, School of Pharmacy, University of Kansas, Lawrence, KS, USA.

Marco Bortolato (M)

Dept. of Pharmacology and Toxicology, College of Pharmacy, University of Utah, Salt Lake City, UT, USA; Dept. of Pharmacology and Toxicology, School of Pharmacy, University of Kansas, Lawrence, KS, USA. Electronic address: marco.bortolato@utah.edu.

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Hormones, substituts d'hormones et antagonistes d'hormones › Antihormones › Inhibiteurs de la synthèse des stéroïdes › Inhibiteurs de la 5-alpha réductase › The steroidogenic inhibitor finasteride...
questionsmedicales.fr › Eucaryotes › Animaux › The steroidogenic inhibitor finasteride...
questionsmedicales.fr › Comportement et mécanismes comportementaux › Comportement › Comportement animal › The steroidogenic inhibitor finasteride...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Pensée (activité mentale) › Prise de décision › Comportement de choix › The steroidogenic inhibitor finasteride...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles animaux de maladie humaine › The steroidogenic inhibitor finasteride...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Effets physiologiques des médicaments › Agents neuromédiateurs › Agents dopaminergiques › Agonistes de la dopamine › The steroidogenic inhibitor finasteride...
questionsmedicales.fr › Composés polycycliques › Composés à cycles fusionnés › Stéroïdes › Stéroïdes hétérocycliques › Azastéroïde › Finastéride › The steroidogenic inhibitor finasteride...
questionsmedicales.fr › Comportement et mécanismes comportementaux › Comportement › Comportement impulsif › The steroidogenic inhibitor finasteride...
questionsmedicales.fr › Système nerveux › Système nerveux central › Encéphale › Prosencéphale › Télencéphale › Cerveau › Noyaux gris centraux › Corps strié › Striatum ventral › Noyau accumbens › The steroidogenic inhibitor finasteride...
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Benzothiazoles › Pramipexole › The steroidogenic inhibitor finasteride...
questionsmedicales.fr › Phénomènes psychologiques › Processus mentaux › Apprentissage probabiliste › The steroidogenic inhibitor finasteride...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Rats › The steroidogenic inhibitor finasteride...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs aux neuromédiateurs › Récepteurs catécholaminergiques › Récepteurs dopaminergiques › Récepteur D2 de la dopamine › Récepteur D3 de la dopamine › The steroidogenic inhibitor finasteride...